Lipoxins as an immune-escape mechanism

Advances in Experimental Medicine and Biology

Volumn 666, Issue , 2009, Pages 78-87

  Machado, Fabiana S ^b   Aliberti, Julio ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ASPIRIN TRIGGERED LIPOXIN A; CD40 ANTIGEN; CELL PROTEIN; CHEMOKINE RECEPTOR CCR5; CYCLOPHILIN 18; GAMMA INTERFERON; GROWTH HORMONE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 12; LIPOXIN; LIPOXIN A; MYELOID DIFFERENTIATION FACTOR 88; PROTEASOME; PROTOZOAL PROTEIN; SOMATOMEDIN C; SUPPRESSORS OF CYTOKINE SIGNALING PROTEIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; GENE; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; LIGAND BINDING; NONHUMAN; PARASITE DEVELOPMENT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SOCS GENE; TOXOPLASMA GONDII; TOXOPLASMOSIS; ANIMAL; HUMAN; IMMUNOLOGY; PHYSIOLOGY; REVIEW; TOXOPLASMA;

TOXOPLASMA GONDII;

ANIMALS; HUMANS; IMMUNE EVASION; LIPOXINS; TOXOPLASMA; TOXOPLASMOSIS;

EID: 75649117821     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1601-3_6     Document Type: Article

References (39)

1. Martinez AJ, Sell M, Mitrovics T et al. The neuropathology and epidemiology of AIDS. A Berlin experience. A review of 200 cases. Pathol Res Pract 1995; 191(5):427-443.
2. Morisaki JH, Heuser JE, Sibley LD. Invasion of Toxoplasma gondii occurs by active penetration of the host cell. J Cell Sci 1995; 108(Pt 6):2457-2464.
3. Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev 2000; 64(3):607-623.
4. Hay J, Hutchison WM. Toxoplasma gondii - An environmental contaminant. Ecol Dis 1983; 2(1):33-43. (Pubitemid 14229632)
5. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: Novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci USA 1984; 81(17):5335-5339. (Pubitemid 14048742)
6. Aliberti J. Host persistence: Exploitation of anti-inflammatory pathways by Toxoplasma gondii. Nat Rev Immunol 2005; 5(2):162-170. (Pubitemid 40208905)
7. Funk CD, Chen XS, Johnson EN et al. Lipoxygenase genes and their targeted disruption. Prostaglandins Other Lipid Mediat 2002; 68-69:303-312. (Pubitemid 35247403)
8. Fiore S, Romano M, Reardon EM et al. Induction of functional lipoxin A4 receptors in HL-60 cells. Blood 1993; 81(12):3395-3403. (Pubitemid 23172926)
9. Fiore S, Maddox JF, Perez HD et al. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med 1994; 180(1):253-260. (Pubitemid 24181074)
10. Schaldach CM, Riby J, Bjeldanes LF. Lipoxin A4: A new class of ligand for the Ah receptor. Biochemistry 1999; 38(23):7594-7600.
11. Mandal PK. Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J Comp Physiol [B] 2005; 175(4):221-230. (Pubitemid 40764087)
12. Aliberti J, Hieny S, Reis e Sousa C et al. Lipoxin-rnediared inhibition ofIL-12 production by DCs: A mechanism for regulation of microbial immunity. Nat Immuno12002; 3(1):76-82. (Pubitemid 34065621)
13. Banncnberg GL, Aliberti J, Hong S et al. Exogenous pathogen and plant IS-lipoxygenase initiate endogenous lipoxin A4 biosynthesis.J Exp Med 2004; 199(4):515-523. (Pubitemid 38233835)
14. Scharton-Kersten TM, Wynn TA, Denkers EYet al. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J Immuno11996; 157(9):4045-4054. (Pubitemid 126449315)
15. Liu CH, Fan YT. Dias A et al. Cutting Edge: Dendritic cells are essential for in vivo IL-12 production and development of resistance against Toxoplasma gondii infection in mice. J Immunol 2006; 177(1):31-35. (Pubitemid 43939111)
16. Reis e Sousa C, Hieny S, Scharton-Kersten T et al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin 12 by dendritic cells and their redistribution to T-cell areas.J Exp Med 1997; 186(11):1819-1829. (Pubitemid 27524592)
17. Aliberti J, Reis e Sousa C, Schito M et al. CCR5 provides a signal for microbial induced production ofIL-12 by CD8 a+ dendritic cells. Nar Immuno12000; 1(1):83-87.
18. Aliberti J, ValenzuelaJG, Carruthers VB et al. Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells. Nat Immunol 2003; 4(5):485-490. (Pubitemid 36592442)
19. Scanga CA, Aliberti J, Jankovic D et al. Cutting edge: My D88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells. J Immunol 2002; 168(12):5997-6001. (Pubitemid 34620012)
20. Yarovinsky F,Zhang D, Andersen JF et al. TLRll activation of dendritic cells by a protozoan profilin-like protein. Science 2005; 308(5728):1626-1629. (Pubitemid 40807512)
21. Hunter CA. Chizzonite R, Remington JS. IL-l beta is required for IL-12 to induce production of IFN-gamma by NK cells.A role for IL-l beta in the T-cell-independent mechanism of resistance against intracellular pathogens. J Immunol 1995; 155(9):4347-4354.
22. Sher A, Oswald lP, Hieny S et al. Toxoplasma gondii induces aT-independent IFN-gamma response in natural killer cells that requires both adherent accessorycells and tumor necrosis factor-alpha. J Immunol 1993; 150(9):3982-3989. (Pubitemid 23129780)
23. Yap GS, Sher A. Cell-mediated immunity to Toxoplasma gondii: Initiation, regulation and effector function. Immunobiology 1999; 201(2):240-247.
24. Karp CL, Wills-Karp M. Complement and IL-12: yin and yang. Microbes Infect 2001; 3(2):109-119. (Pubitemid 32209328)
25. Son ES. Song KJ, Shin JC et al. Molecular cloning and characterization of peroxiredoxin from Toxoplasma gondii. KoreanJ Parasitol2001; 39(2):133-141.
26. Leonard MO. Hannan K, Burne MJ et al. 15-Epi-16-(para-fluorophenoxy)- lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 2002; 13(6):1657-1662. (Pubitemid 34579255)
27. Kile BT, Schulman BA, Alexander WS et al. The SOCS box: A tale of destruction and degradation. Trends Biochem Sci 2002; 27(5):235-241. (Pubitemid 34655444)
28. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004; 22:503-529. (Pubitemid 38680432)
29. Start R, Mercalf D, Elefanty AG et al. Liver degeneration and lymphoid deficiencies in mice lacking suppressor of cytokine signaling- 1 Proc Narl Acad Sci USA 1998; 95(24):14395-14399. (Pubitemid 28549378)
30. Marine JC, McKay C, Wang D er al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999; 98(5):617-627. (Pubitemid 29418953)
31. Metcalf D. Greenhalgh CJ, Viney E et al. Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000; 405(6790):1069-1073. (Pubitemid 30447793)
32. Kopchick JJ, Bellush LL, Coschigano KT. Transgenic models of growth hormone action. Annu Rev Nutr 1999; 19:437-461. (Pubitemid 29380612)
33. Colao A, Merola B, Ferone D et al. Acromegaly. J Clin Endocrinol Metab 1997; 82(9):2777-2781.
34. Bradford GE. Famula TR. Evidence for a major gene for rapid postweaning growth in mice. Genet Res 1984; 44(3):293-308. (Pubitemid 15172023)
35. Machado FS.Johndrow JE. Esper L et al. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nat Med 2006; 12(3):330-334. (Pubitemid 43355082)
36. Hachicha M. Pouliot M. Petasis NA et al. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit turnor necrosis factor Ialpha-initiared neutrophil responses and trafficking: Regulators of a cytokine-chernokine axis.J Exp Med 1999; 189(12):1923-1930.
37. Machado FS. Esper L. Dias A et al. Native and aspirin-triggered lipoxins control innate immunity by inducing proteasomal degradation of TRAF 6 J Exp Med 2008; 205(5):1077-1086. (Pubitemid 351679683)
38. Choi Y. Role of TRAF 6 in the immune system. Adv Exp Med Bioi 2005; 560:77-82.
39. Lomaga MA. YehWC. Sarosi 1 et al. TRAF6 deficiency results in osteopetrosis and defective interleukin- l , CD40 and LPS signaling. Genes Dev 1999; 13(8):1015-1024. (Pubitemid 29200984)